From HAE Scandinavia
We are pleased to inform you about new treatment options in Scandinavia. In Norway, ORLADEYO™ (capsule) was approved on 1 December 2021 for the preventive treatment of HAE in adults and adolescents/children from 12 years of age. In Sweden, both ORLADEYO™ (capsule) and TAKHZYRO™ (injection under the skin) were approved on 1 January 2022 for the preventive treatment of HAE in adults and adolescents/children from 12 years of age.
The Danish Medicines Council has just recommended ORLADEYO™ (capsule) as a preventive treatment for HAE in adults and adolescents/children from 12 years.
